Panitumumab

BNF:
8.1.5
Status:
Do Not Prescribe (DNP), Red
Decision Date:
None
 

Comments

DO NOT PRESCRIBE (DNP): NICE TA240: Colorectal cancer metastatic. Unable to recommend NHS use - TA terminated due to lack of evidence submission (decision date - January 2012)

DO NOT PRESCRIBE (DNP): NICE TA242: Colorectal cancer (metastatic) 2nd line. Panitumumab – not recommended (decision date - February 2012)

RED 1,2,3 : NICE TA439 - cetuximab and panitumumab for previously untreated metastatic colorectal cancer. (decision date -  May 2017)

 

(This drug can be funded through the cancer drug fund - seek advice from the oncologist/haematologist)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app